Can you quantify "cheap" for me please?
I've said this before, a $600M MC company with a few sales, a FDA and a marketing plan seems pretty expensive. People use the term "cheap" and use their own wishful thinking as valuation.
If we reverse engineer current valuation, on a 25xPE, would mean NPAT of $24M. Based on best estimates provided by analysts, this woud suggest that 850,000 prescriptions to be filled in the USA.
I get that the market is forward looking, but its already valued at 2025/26 sales estimates.
Bot Chart, page-13300
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.3¢ |
Change
-0.003(0.65%) |
Mkt cap ! $696.8M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.5¢ | $1.184M | 3.090M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 490899 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 284646 | 16 |
View Market Depth
| Last trade - 12.53pm 17/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |